With BMS Set To Join, What Next For CAR-T Market?
Outpatient Use Will Be Key
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?
You may also be interested in...
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.